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Abstract: Chondrocyte exposure to inflammatory stimuli in  several arthritic conditions, including 
osteoarthritis, results in the well-characterized induction of extracellular matrix degrading pro-
teinases, notably members of a disintegrin and metalloproteinase (ADAM) with thrombospondin 
domains and matrix metalloproteinase families. Here we briefly review the less-studied ADAM 
family of proteinases in chondrocyte and cartilage biology. Following damage, cartilage is exposed 
to neurovascular peptides, and in this study we hypothesized that substance P and bradykinin, 
alongside inflammatory cytokines, may modulate chondrocyte steady-state messenger RNA 
levels for the proteolytic ADAM family members as well as for key cytokines and neuropeptides. 
We compared chondrocytes cultured in both two-dimensional and three-dimensional (3D) envi-
ronments and found that 3D culture generally resulted in repression of expression of the genes 
under investigation, with the exception of anti-inflammatory interleukin 10 which was markedly 
upregulated in a 3D environment. Substance P and bradykinin had little effect on ADAM family 
expression, but further investigation revealed that a combination of bradykinin and cytokines led 
to enhanced expression of ADAM28 and a synergistic upregulation of interleukin 6, also observed 
under hypoxic conditions. Overall these data reveal wider chondrocyte responses to neurovascular 
peptides which may have an impact in an osteoarthritis context.
Keywords: chondrocyte, ADAM, metalloproteinase, cytokine; bradykinin
Introduction
The cartilage environment
Chondrocytes are surrounded by an extensive extracellular matrix comprising type II 
collagen and aggrecan as well as a large number of other collagens, proteoglycans, and 
proteins together providing a remarkable, unique environment. Chondrocytes lack the 
capacity to drive efficient repair and thus in osteoarthritis (OA) articular cartilage is 
irreversibly damaged. While earlier studies viewed OA as a wear-and-tear condition, 
there is now a consensus, reviewed by Konitten et al,1 that chondrocytes both respond 
to and may themselves produce proinflammatory cytokines which can result in carti-
lage breakdown through modulating the expression of metalloproteinases including a 
disintegrin and metalloproteinase with thrombospondin domains (ADAMTS) enzymes, 
matrix metalloproteinases (MMPs), and serine proteinases.2
Interplay of pain-related neurovascular peptides with 
cartilage biology
OA is increasingly viewed as a disease of the whole joint, including cartilage, synovium, 
bone, and, in knee OA, the infrapatellar fat pad.3,4 Adult cartilage is avascular and the 
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resulting hypoxic environment promotes chondrocyte dif-
ferentiation,5–7 in addition to maintaining the chondrocyte 
phenotype.8 Cartilage is also aneural, but damaged carti-
lage is recognized as a potentially permissive environment 
for neurovascular infiltration.9–11 Sensory nerve fibers thus 
accompany new blood microvessels that grow into damaged 
cartilage in OA. 
While effects of several cytokines and chemokines on 
neuronal excitation have been explored,12 as yet the effects 
of neurovascular factors on chondrocyte gene expression and 
function remain less studied. Several neuropeptides, which 
play key roles in transmission of pain signals from the periph-
ery to the central nervous system, are upregulated in joint 
disease. For example, substance P is elevated in the synovial 
fluid in both OA and rheumatoid arthritis (RA) joints, and 
the expression of substance P is particularly associated with 
more active OA.13 Im et al13 also  demonstrated that substance 
P and its receptor NK1-R are expressed at higher levels in 
human articular cartilage from OA patients than controls. 
Substance P is produced in nerve fibers of the intracellular 
fat pad where a role in inflammation and cartilage destruction 
has been suggested.4 
Kinins, including bradykinin, are often associated with 
acute and chronic inflammation, and, more recently, attention 
has turned to potential roles in OA. Bradykinin is a vasodi-
lator with established roles in inflammation and a number 
of studies show that it is elevated in OA synovial fluid.14 
An antagonist of bradykinin has been shown to reduce pain 
levels in a small study of patients with very painful OA.15 
Functional bradykinin receptors are expressed in human 
chondrocytes with evidence of release of inflammatory 
cytokines interleukin (IL)6 and IL8 following bradykinin 
stimulation.16 The synovial compartment, which is itself 
innervated, may also respond to neuropeptide release and 
bradykinin is important in synovitis in OA.17 A more recent 
study showed that an antagonist of bradykinin receptor B 
(BDKRB)1 provides protection against joint injury in the rat 
anterior cruciate ligament model.18 In addition, a polymor-
phism in BDKRB2 is associated with both higher risk and 
higher severity of OA in one study.19 
As well as roles in regulation of gene expression, neu-
ropeptides may also modify aspects of chondrocyte biology 
including cell proliferation and migration. Chondrocytes can 
migrate in vitro and in vivo in development and possibly in 
OA.20 Opolka et al21 demonstrated that substance P can induce 
proliferation of murine newborn costal chondrocytes and 
elevate cell adhesion and focal contact formation, indicating 
novel roles in cell-matrix interactions. 
ADAMs in chondrocytes and cartilage
A disintegrin and metalloproteinase (ADAM) family mem-
bers with proteolytic activity may play roles in chondrocyte 
biology and OA. While regulation of both MMPs and 
ADAMTS proteinases has been studied extensively in chon-
drocytes, less attention has been given to the ADAM family. 
Several ADAMTS proteinases can degrade proteoglycans22 
and ADAMTS4 and 5 are known to play key roles in pro-
teoglycan degradation in cartilage with human ADAMTS5 
showing 1,000-fold greater aggrecan degradative capacity 
than ADAMTS4 in biochemical analyses.23 Both enzymes 
can degrade aggrecan in human cartilage explants22 and 
recently developed antibodies specifically block ADAMTS5 
aggrecan fragment release,24 in one case to a far greater 
extent than possible through blockade of ADAMTS4.25 In 
addition adamts5 (but not adamts4) null mice are protected 
from experimentally induced OA.26,27 
ADAMs have a structure comprising a propeptide, 
catalytic, disintegrin, cysteine-rich, transmembrane, and 
cytoplasmic domains and are furin-activated (furin cleav-
age site located between pro- and catalytic domains).28 
As transmembrane enzymes, ADAMs are well placed for 
their extensive shedding functions, where cell adhesion 
molecules, growth factors, and their receptors among 
many other proteins are cleaved and thus shed from the cell 
surface.29 Certain MMPs share shedding functions (includ-
ing, for example, MMP9), but this seems to be a function 
mainly restricted to ADAMs. Through their disintegrin 
domains, several ADAMs can bind to integrins, a function 
also observed with certain MMPs (even though in MMPs 
disintegrin domains are absent),30 but ADAMTS enzymes, 
despite the presence of a disintegrin domain, seem to lack 
this function.28 Several proteolytic ADAMs are expressed 
in chondrocytes or OA cartilage.31,32 Here, we briefly review 
findings regarding ADAMs with proteolytic activity where 
expression and/or function relating to chondrocyte biology 
and/or OA have been reported.
ADAM8
Expression of ADAM8 has been observed in cartilage during 
mouse development,33 and expression of an inactive ADAM8 
mutant results in protection against murine experimental 
inflammatory arthritis.34 In addition, ADAM8 is expressed 
in OA cartilage, and when isolated from chondrocyte culture 
medium, this protease is able to cleave fibronectin.35 This is 
an important finding, since fibronectin fragments are found 
in damaged joint tissues and are able to induce MMP gene 
expression and aggrecan degradation in cartilage.36
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ADAM9
Flannery et al37 showed the downregulation of ADAM9 expres-
sion in IL1-treated porcine chondrocytes in three-dimensional 
(3D) compared to two-dimensional (2D) culture,37 and this 
proteinase is expressed during human mesenchymal cell dif-
ferentiation along the chondrocyte lineage.38 ADAM9 expres-
sion is upregulated in end-stage OA cartilage.23
ADAM10
Earlier studies revealed increased ADAM10 mRNA levels in 
IL1-treated bovine chondrocytes,37 and enhanced ADAM10 
protein levels were observed in OA compared to healthy 
cartilage and in IL1-stimulated bovine nasal cartilage.39 
More recent observations indicate that ADAM10 cleavage 
of the cell adhesion molecule, N-cadherin, has an important 
role in chondroprogenitor cell–cell interactions leading to 
condensation and differentiation.40 
ADAM12
This ADAM has been associated with OA in genetic 
studies,41,42 and ADAM12 mRNA and protein (by immu-
nocytochemistry) levels are upregulated in end-stage OA 
cartilage.22,23 ADAM12 plays a role in chondrocyte prolifera-
tion through cleavage of insulin-like growth factor binding 
protein (IGFBP)-5,22 which may be important in attempted 
repair by chondrocytes in OA. 
ADAM15
IL1 was shown to enhance the expression of ADAM15 in 
monolayer cultures of porcine chondrocytes37 and ADAM15 
(also known as metargidin) is upregulated in end-stage OA 
cartilage.43 Interestingly, ADAM15 null mice developed a 
more accelerated OA,44 suggesting that ADAM15 is protec-
tive against the development of OA. Later studies revealed 
that ADAM15 is anti-apoptotic in OA chondrocytes and pro-
motes cell adhesion to type II collagen when overexpressed 
in chondrocytes.45 The anti-apoptotic mechanism involves 
ADAM15 cytoplasmic tail interaction with focal adhesion 
kinase (FAK) resulting in enhanced FAK phosphorylation 
and promotion of cell survival under genotoxic conditions.46 
ADAM17
Due to its role in shedding of tumor necrosis factor alpha 
(TNFα), along with cleavage of other relevant molecules, 
ADAM17 has been highly associated with RA.47 Soluble IL6-
receptor (sIL6-R) is often generated through ADAM17 cell 
surface cleavage, enabling sIL6-R to increase  IL6-mediated 
cartilage damage. A very recent study has shown that 
ADAM17-mediated shedding of IL6-R is blocked by secreted 
frizzled-related protein 3 (sFRP3) and the rare OA double-
mutant variant of sFRP3 loses this inhibitory capacity.48 This 
could result in greater release of sIL6-R and hence enhanced 
IL6 signaling leading to further cartilage destruction. 
ADAM19
Expression of this ADAM is elevated during in vitro dif-
ferentiation of human chondrocytes.38 ADAM19 can shed 
TNFα from the cell surface,49 though this has not as yet been 
demonstrated in chondrocytes.
ADAM28
ADAM28 is not observed in undamaged human cartilage; 
however, it is expressed in end-stage OA cartilage.23 More 
recently, a proteomic approach found ADAM28 in the peri-
cellular matrix of chondrocytes in articular cartilage.50 Since 
ADAM28 can degrade IGFBP-3,51 it is possible that this 
proteinase plays a role in chondrocyte proliferation, as has 
been demonstrated for breast cancer cells.52 Another function 
of ADAM28 appears to be in the shedding of TNFα from the 
cell surface, demonstrated in monocytes and which may be of 
relevance in arthritic conditions.53 ADAM28 can be regulated 
by 9-cis retinoic acid and peroxisome proliferator-activated 
receptor gamma ligands in differentiated monocytes,54 as 
well as by 9-cis retinoic acid in chondrocytes,55 indicating 
the involvement of potentially similar pathways across cell 
types. ADAM28 also degrades human chondrocyte proteo-
glycans,55 such that co-culture of bovine nasal cartilage discs 
with ADAM28-expressing COS-7 cells results in greater 
proteoglycan release.55
Neurovascular peptides and 
metalloproteinase expression
Studies on neurovascular peptides substance P and bradyki-
nin in an arthritic context have to date focused on MMP or 
ADAMTS expression. Miller et al12 showed that  treatment 
of cartilage fragments with substance P in combination with 
fibroblast growth factor 2 results in cartilage degradation. 
In addition, exposure of human chondrocytes to increasing 
concentrations of substance P leads to enhanced expression 
of several MMPs.13 Taken together, these data suggest that 
substance P may be an important regulator of catabolism 
of articular cartilage in OA. Bradykinin levels correlate 
with  glycosoaminoglycan fragments in synovial fluid of OA 
patients,56 which could suggest a link to matrix degrada-
tion. Bradykinin is also known for its ability to induce the 
 activation of the ADAM17-EGFR transactivation pathway57 
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and to  indirectly enhance MMP production in a number of 
other cell types, but this has not been explored in chondrocytes.
The potential interplay between neurovascular peptides 
released in the OA joint and ADAM proteinase expression 
remains little explored. We hypothesized that a 3D culture 
environment may regulate chondrocyte responses to cytokines 
and neurovascular peptides. Specifically in the experiments 
reported here, we have surveyed the expression of genes 
encoding proteolytic ADAM family members, tissue inhibi-
tors of metalloproteinases (TIMPs) and selected cytokines/
neuropeptides and receptors in chondrocytes in response to 
the cytokines IL1α and oncostatin M (OSM), substance P, and 
bradykinin in both 2D and 3D culture environments.
Materials and methods 
Materials
Unless otherwise stated chemical reagents were purchased 
from Sigma Aldrich, Gillingham, UK, culture media from 
Gibco Thermo Fisher Scientific, UK, and tissue culture 
plastics from Nunc Thermo Scientific, UK.
Cell culture model
C28I/2 chondrocytes were cultured essentially as previously 
described58 in DMEM with 10% fetal calf serum (FCS) at a 
cell density of 190,000 cells/24 well in 2D monolayer culture 
or in a 3D model with culture of chondrocytes over poly-
HEMA,58 for a total of 96 hours. During the final 24 hours, 
the cells were stimulated with a combination of IL1α (10 ng/
mL) and OSM (5 ng/mL), bradykinin (1 µM), or substance 
P (100 µM) in DMEM with 1% FCS. Where indicated cells 
were also exposed to a hypoxic environment (1% oxygen in a 
Billins chamber) for 24 hours prior to and during treatments. 
RNA extraction, TaqMan low-density 
array, and qRT-PCR analysis
Following cell lysis, RNA was extracted using the RNeasy plus 
mini kit (Qiagen)  according to the manufacturer’s instructions. 
Total RNA (1 µg) was reverse transcribed with 1 µg random 
primer oligonucleotides (Invitrogen, Paisley, UK) and 200 units 
of M-MLV reverse transcriptase (Promega, Southampton, UK). 
cDNA samples were analyzed on custom-designed TaqMan 
low-density array (TLDA) plates (Applied Biosystems, War-
rington, UK) to detect the expression of the genes encoding 
ADAMs 8, 9, 10, 12, 15, 17, 19, 20, 21, 22, 28, 33, TIMPs 1–4, 
the cytokines IL6 and IL10, the neurotrophins nerve growth 
factor (NGF) and brain-derived neurotrophic factor (BDNF), 
neuropeptide Y (NPY), and bradykinin receptors and the house-
keeping  gene 18S. (ADAM22 was included in this initial TLDA 
screen as, while it lacks proteolytic  activity, ADAM22 expres-
sion is highly upregulated in OA cartilage compared to healthy 
cartilage, at least at the mRNA level23). Prior to TLDA analysis, 
samples were analyzed on geNorm (Primer Design; Qiagen, 
Manchester, UK) where 18S ribosomal RNA was found to be 
the least-regulated housekeeping gene (of the 12 explored) 
for all treatment regimens (data not shown). TLDA analysis 
was performed in triplicate for each condition. A total of 150 
ng of RNA was loaded into each port of the TLDA plates and 
analyzed in an ABI 7900HT Instrument (Applied Biosystems). 
QRT-PCR  using an ABI prism 7500 sequence detection 
system (Applied Biosystems) was performed as previously 
described59 with primer probe sets from Applied Biosystems. 
Genes were analyzed using predesigned Applied Biosystems 
inventorized primer probe sets (Table 1) or primer probe sets 
designed using Primer Express 1.0 Software (Applied Biosys-
tems; Table 1). Primers were designed spanning exon–intron 
boundaries to avoid amplification of genomic DNA and were 
tested for specificity by BLAST analysis. 18S ribosomal RNA 
was used as an endogenous control to normalize for  differences 
Table 1 Inventorized primer set codes for TLDA analysis and for 
further experimentation (ADAM28)
Gene ABI inventorized primer set
ADAM9 Hs00177638_m1
ADAM10 Hs00153853_m1
ADAM12 Hs01106101_m1
ADAM15 Hs00984794_m1
ADAM17 Hs01041915_m1
ADAM19 Hs00224960_m1
ADAM20 Hs01083178_s1
ADAM21 Hs01652548_s1
ADAM22 Hs00244640_m1
ADAM28 Hs00248020_m1
ADAM33 Hs00905552_m1
TIMP1 Hs00171558_m1
TIMP2 Hs00234278_m1
TIMP3 Hs00165949_m1
TIMP4 Hs00162784_m1
IL6 Hs00985639_m1
IL10 Hs00961622_m1
BDNF Hs00380947_m1
NGF Hs00171458_m1
NPY Hs00173470_m1
Tachykinin 3 Hs00203109_m1
BDKRB1 Hs00664201_s1
BDKRB2 Hs00176121_m1
ADAM28 Forward: 5´- GGGCCCACGATTTGCA-3´
Reverse: 
5´-TGAACCTTCCTGTCTTTCAATTTTACT-3´
Probe: 5´FAM-
AGAACATTGCCCTACCTGCCACCAAAC-
TAMRA-3
Abbreviations: ADAM, a disintegrin and metalloproteinase; TLDA, TaqMan low-
density array; TIMP, tissue inhibitors of metalloproteinase; IL, interleukin; BDNF, 
brain-derived neurotrophic factor; NGF, nerve growth factor; NPY, neuropeptide 
Y; BDKRB, bradykinin receptor B.
 
M
et
al
lo
pr
ot
ei
na
se
s 
In
 M
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
22
2.
80
.1
25
 o
n 
28
-S
ep
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Metalloproteinases In Medicine 2016:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
3D culture modulates ADAM expression in chondrocytes
in the amount of total RNA in each sample (18S rRNA primers 
and probe were purchased from Applied Bioscience).
Results
Effects of culture in 3D and of cytokine 
stimulation
Of the 12 ADAMs whose steady-state mRNA expression was 
determined, eleven showed modulation of expression in chon-
drocytes by TLDA analysis (Figure 1; Table 2). 3D culture 
resulted in the downregulation of steady-state mRNA levels 
of seven of the ADAMs expressed in chondrocytes, with 
ADAM9, ADAM20, and ADAM33 mRNAs showing at least 
a twofold suppression (Figure 1; Table 2). TIMP2 mRNA was 
also significantly repressed, but other TIMPs were unaffected 
by 3D culture. Cytokine stimulation resulted in the upregula-
tion of expression of several ADAM mRNAs in 2D, but in 
3D culture, this was restricted to ADAMs12 and 28 (Table 
2). Interestingly, ADAM10 and ADAM15 mRNAs were no 
longer modulated by cytokines when cells were cultured in 
3D and that of ADAM19 and ADAM21 was now repressed 
(Table 2). TIMP1 mRNA was increased by cytokines in both 
2D and 3D cultures, whereas that of TIMP3 was repressed by 
cytokines in both culture environments (Table 2). 
We surveyed a small number of receptors for neuropep-
tides as well as neurotrophins and cytokines. It is interest-
ing to note that cytokines upregulated the expression of 
bradykinin receptors 1 and 2 both in 2D and in 3D cultures 
of chondrocytes. In addition IL6 and IL10 mRNAs were 
strongly upregulated by cytokines in both 2D and 3D (Table 
2). In contrast, cytokines repressed the expression of BDNF, 
NPY, and tachykinin 3 in both culture environments. 
Effects of substance P and bradykinin
Substance P treatment slightly upregulated ADAM17 mRNA 
(1.4-fold) but bradykinin did not alter ADAM expression in 
2D culture. In chondrocytes in 3D culture, substance P and 
bradykinin both significantly repressed the gene expression 
of several ADAMs (Figure 1; Table 2). Substance P repressed 
TIMPs 2 and 3 whereas bradykinin repressed TIMPs 2 and 4, 
respectively (Figure 1; Table 2). Steady-state mRNA levels 
of few other genes were modulated by either substance P or 
bradykinin (Figure 1; Table 2).
Effects of co-stimulation with 
neurovascular peptides and cytokines 
under normoxic and hypoxic conditions
In general, little overlap of induction of gene expression 
was observed under different stimuli. The small number of 
genes regulated by substance P or bradykinin alone led us 
to explore the effects of co-stimulation with cytokines and 
these neurovascular peptides. We were particularly interested 
to explore further the regulation of ADAM28 since this pro-
teinase has recently been found in the pericellular matrix of 
chondrocytes.50 We pursued its expression alongside that of 
IL6, since this cytokine was upregulated by several stimuli. 
We exposed cells in 3D culture to cytokines or neuropeptides 
both alone and in combination with cytokines under normoxic 
and hypoxic conditions. 
In 3D culture under normoxic conditions, we confirmed 
the upregulation of expression of ADAM28 in the presence 
of cytokines. Interestingly expression was further enhanced 
by co-stimulation with bradykinin (Figure 2A). A further 
TLDA survey of the other proteolytic ADAMs did not reveal 
any effect of bradykinin on their expression in the presence 
of cytokines (results not shown). Preliminary investigations 
revealed that exposure of chondrocytes to hypoxic conditions 
significantly upregulated ADAM28 mRNA by 3.7-fold and 
in the presence of cytokines alone no further regulation was 
observed. However, under hypoxic conditions co-stimulation 
with bradykinin led to further upregulation of ADAM28 
mRNA (Figure 2A). Cytokine induction of IL6 mRNA was 
confirmed in 3D culture under normoxic conditions and an 
apparently synergistic induction with bradykinin co-stimula-
tion was observed (Figure 2B). In contrast to ADAM28, the 
cytokine-induced expression of IL6 mRNA was suppressed 
under hypoxic conditions (2.4-fold) but synergistic induction 
with co-stimulation with bradykinin was again observed 
(Figure 2B). Expression of TNFα was also explored but no 
synergy with bradykinin was observed (data not shown).
Discussion
Neurovascular mediators including substance P and brady-
kinin are released into the synovial fluid in both OA and RA 
and are involved in pain perception. Here we show that the 
cellular environment has profound effects on constitutive 
ADAM expression as well as on the modulating effects of 
soluble mediators, either cytokines or neurovascular peptides. 
3D suspension culture results in 
downregulation of mRNA levels for many 
genes studied
Overall, we observed that the culture of chondrocytes in 3D sig-
nificantly repressed steady-state mRNA levels of seven ADAMs 
including ADAM9, as well as IL6, TIMP2, BDNF, and NGF. 
Downregulation of ADAM9 mRNA in chondrocytes has been 
reported previously in 3D cultures.37 Collagen I downregulation 
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Table 2 Modulation of steady-state mRNA levels for ADAMs, TIMPs, cytokines, and neurovascular factors under the indicated 
conditions, determined by TLDA analysis
Gene 3D versus 2D IL1/OSM (2D) IL1/OSM (3D) SubP (2D) SubP (3D) BK (2D) BK (3D)
ADAM9 –2.1 ↔ –2.5 ↔ –1.5 ↔ –1.7
ADAM10 –1.7 2 ↔ ↔ ↔ ↔ ↔
ADAM12 –1.7 4 2 ↔ –1.7 ↔ –1.7 
ADAM15 –1.6 1.4 ↔ ↔ –1.4 –1.4
ADAM17 –1.4 ↔ ↔ 1.4 ↔ ↔ ↔
ADAM19 ↔ 1.7 –1.4 ↔ –1.7 ↔ ↔
ADAM20 –2.7 2 ↔ ↔ ↔ ↔ ↔
ADAM21 ↔ ↔ –2 ↔ ↔ ↔ ↔
ADAM22 ↔ ↔ ↔ ↔ –1.9 ↔ ↔
ADAM28 ↔ ↔ (2; P=0.09) ↔ ↔ ↔ ↔
ADAM33 –2 ↔ ↔ ↔ ↔ ↔ ↔
TIMP1 ↔ 2 2.5 ↔ ↔ ↔ ↔
TIMP2 –1.5 ↔ ↔ ↔ –1.5 ↔ –1.7
TIMP3 ↔ –2 –4 ↔ –1.6 ↔ ↔
TIMP4 ↔ ↔ ↔ ↔ ↔ ↔ –1.8
IL6 –2 77 55 2.7 ↔ ↔ ↔
IL10 5.9 65 13 ↔ ↔ ↔ ↔
BDNF –2.3 –2.2 –3.5 ↔ ↔ ↔ ↔
NGF –4 ↔ ↔ ↔ ↔ ↔ ↔
NPY ↔ –4.2 –3.5 ↔ –1.7 ↔ ↔
Tachykinin 3 ↔ –2.5 –2.1 ↔ ↔ ↔ ↔
BDKRB1 ↔ 5.3 4.1 1.7 ↔ ↔ ↔
BDKRB2 ↔ 2.2 2 ↔ ↔ ↔ ↔
Notes: Significant fold changes are indicated compared to unstimulated cells in either 2D or 3D culture (or comparison between 2D and 3D for unstimulated cells only). 
↔ indicates no change.
Abbreviations: IL1/OSM, interleukin 1/oncostatin M; subP, substance P; BK, bradykinin; ADAM, a disintegrin and metalloproteinase; TIMP, tissue inhibitor of 
metalloproteinase; IL6, interleukin 6; IL10, interleukin 10; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; NPY, neuropeptide Y; BDKRB1, bradykinin 
receptor B1; BDKRB2, bradykinin receptor B2; TLDA, TaqMan low-density array.
was observed in primary chondrocytes in a 3D culture model 
similar to that used here 60 (indicative of chondrocyte redif-
ferentiation) and we observed similar results in our cultures 
(data not shown). Repression of IL6 mRNA in 3D collagen 
gel culture (compared to culture on a thin coating of collagen) 
was observed previously in ovarian tumor cells.61 Future stud-
ies will reveal whether similar mechanisms are involved in 
downregulation of steady-state mRNA levels for the 11 genes 
affected by 3D culture in our studies. Uniquely among the 
genes explored in our study, the anti-inflammatory cytokine, 
IL10, was upregulated in cells cultured in 3D. In relation to 
this finding, it is interesting to note that fibroblasts cultured in 
a 3D matrix of enhanced stiffness in a wound healing context 
express greater levels of IL10.62 Taken together, our data on 
IL6 and IL10 suggest that chondrocytes in a 3D environment 
have an overall anti-inflammatory phenotype. 
Effects of cytokines and neurovascular 
peptides
We exposed chondrocytes to a standard combination of IL1α 
and OSM since these cytokines have previously been shown to 
be present in synovial fluid of OA patients63 and have long been 
known to act synergistically to induce complete breakdown 
of both bovine nasal cartilage64 and human OA cartilage.65 
ADAMs
In 2D culture, cytokine treatment upregulated the steady-
state mRNA levels for six ADAMs, several of which were 
previously reported to be expressed in chondrocytes or 
OA cartilage.31,32 In our 3D cultures, we no longer saw 
cytokine-mediated upregulation of ADAM10, ADAM15, 
and ADAM19, and this could reflect the overall suppres-
sive nature of the 3D environment. ADAM12 mRNA was 
elevated by cytokines in both 2D and 3D culture, with 
overall expression levels approximately halved in 3D 
compared to monolayer culture. Recently an ADAM12 
SNP associated  with severity of knee OA was reported.42 
ADAM12 (among other ADAMs) can shed the cell surface 
receptor LRP-1  which mediates endocytosis of TIMP3 
and aggrecan-degrading ADAMTS5.66 Thus, alterations 
in ADAM12 levels could indirectly have consequences on 
cartilage degradation. 
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In our initial survey, ADAM28 showed a trend toward 
increased expression following cytokine treatment in 3D 
culture (confirmed in our later experiment) and overall 
expression levels were not repressed in 3D, in contrast to other 
ADAMs. Cytokines regulate ADAM28 in monocytic cells53 
and ADAM28 expression is elevated in peripheral blood 
mononuclear cells in Kashin–Beck disease, characterized 
by chondrocyte necrosis.67 We saw a trend toward increase 
in expression with bradykinin treatment alone, but this did 
not reach significance. 
TIMP3
TIMP3 expression was repressed following cytokine treat-
ment, an effect seen in synovial cells68 and observed in 
endothelial cells by us in previous studies.69 Substance P also 
repressed TIMP3 mRNA levels in 3D culture, suggesting a 
Figure 2 Confirmation of co-stimulatory effects of bradykinin and cytokines in chondrocytes cultured in 3D.
Notes: (A) ADAM28 steady-state mRNA levels are elevated by a combination of cytokines and bradykinin under normoxic conditions (red bars) and are maintained 
under hypoxic conditions (blue). (B) IL6 expression is synergistically enhanced by the combination of cytokines and bradykinin under normoxic conditions (red) and overall 
responses are reduced under hypoxic conditions (blue). Steady-state mRNA levels for ADAM28 and IL6 were determined by qRT-PCR. For this fold-change analysis, control 
(unstimulated) cells were set as 1. Each bar represents the mean ± SEM for triplicate samples following normalization to 18S RNA. *P<0.05; **P<0.02; ***P<0.01.
Abbreviations: ADAM, a disintegrin and metalloproteinase; IL, interleukin; OSM, oncostatin M
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potentially important role for this neuropeptide in cartilage 
homeostasis. TIMP3 deletion in mice results in the degrada-
tion of collagen and aggrecan over time and development of 
OA-like symptoms,70 and very recently, a TIMP3 polymor-
phism associated with the severity of knee OA was reported,71 
although any functional consequences remain unknown. As 
well as inhibiting many MPs  involved in cartilage degrada-
tion (for example, ADAMTS5 and MMP13), TIMP3 also 
inhibits ADAM17 and other sheddases. Thus the repression 
of TIMP3 mRNA observed here may also have profound 
consequences on the cell surface ecology of chondrocytes. 
Cytokines
The increase in steady-state mRNA levels for anti-inflam-
matory IL10 seen in response to cytokines in both 2D and 
3D may reflect an attempt to counteract the damaging effects 
of proinflammatory cytokine stimulation. Exogenous IL10 
can protect against cartilage damage72 and IL10 levels are 
upregulated in OA and postulated to be a prorepair response.73 
Cytokine upregulation of IL6 is in agreement with previous 
findings in OSM-treated mouse articular chondrocytes, for 
example, where a hierarchy of responses suggests that OSM 
may be a better therapeutic target than IL6.74 Cytokines 
repressed neurotrophin BDNF expression as well as that of 
NPY and tachykinin 3 (both in 2D and in 3D). Perhaps of 
relevance is the finding that levels of BDNF are enhanced 
after exercise in patients with knee OA and may have anti-
inflammatory benefits with corresponding improved pain 
scores.75
Bradykinin and cytokine co-stimulation: 
effects on ADAM28 and IL6 expression
Enhanced expression of ADAM28 in the presence of cyto-
kines and bradykinin may be due to the increased bradykinin 
receptor expression observed in the presence of cytokines 
alone. The synergistic increase in IL6 expression with cyto-
kine and bradykinin co-treatment in normoxia is reminiscent 
of that seen in an early study in gingival fibroblasts where 
IL6 protein production was elevated by stimulation with 
bradykinin and IL1 or TNFα.76 Similar synergistic effects of 
bradykinin and IL1β on the expression of COX-2 and PGE-2 
in synoviocytes have been observed.77 These authors dem-
onstrated that this effect was mediated by bradykinin recep-
tors, using the inhibitor fasitibant, and was dependent on the 
NFkB  pathway. Future studies will determine mechanisms 
underpinning the upregulation of steady-state mRNA levels 
for ADAM28 and IL6 seen with bradykinin and cytokine 
co-stimulation in chondrocytes.
In our preliminary study, hypoxia exerted a positive effect 
on both constitutive and cytokine-induced ADAM28 mRNA 
levels but was suppressive for IL6 (and for the expression 
of several other genes; data not shown). Several studies 
have explored IL6 gene expression and/or protein secretion 
under various levels of hypoxia with 3% oxygen resulting in 
upregulation of IL6 secretion in human synovial cells,78 but 
5% oxygen leading to downregulation in placental cells.79 
Previous work showed that hypoxia (1% oxygen as used 
in our study) promotes chondrocyte differentiation7 and 
perhaps the repression of IL6 under hypoxic conditions is 
anti-inflammatory and prorepair.
Overall our experiments demonstrate interesting 
and novel regulation of steady-state mRNA levels for 
ADAMs and cytokines in C28/I2 chondrocytes, a read-
ily available immortalized human culture model. Future 
experiments will reveal mechanisms underpinning our 
observations as well as any parallels in primary human 
chondrocytes and cartilage.
Limitations of the study
While we have demonstrated novel effects of neurovascular 
peptides and hypoxic conditions on ADAM and cytokine 
steady-state mRNA levels, we have not confirmed effects 
at the protein level nor have we explored functional con-
sequences of any changes in expression. Future studies 
following confirmation of protein levels would include 
functional assessment of enzyme activity with relevant 
substrates and gene silencing approaches to determine, for 
example, ADAM28’s role in proteoglycan degradation/cell 
proliferation in chondrocytes under bradykinin and cytokine 
stimulation.
Conclusion
This study reveals the novel regulation of ADAM proteinases 
at the mRNA level by a 3D culture environment which also 
modulates cytokine responses in chondrocytes. In addition, 
steady-state mRNA levels of ADAM28 and IL6 are elevated 
by bradykinin, in the presence of cytokines, which may rep-
resent an important modulator of the chondrocyte milieu. 
These findings pave the way for future studies of the impact 
of bradykinin and downstream pathways on cartilage function 
under inflammatory stress.
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